Novel mutation in KCNJ2 gene causes long QT interval syndrome type 7 and learning disability: A case report

Clinical management is mostly focused on reducing adverse cardiac events. As a first option, β-blockers are often chosen as treatments for LQT7 patients, but there is no clear evidence for their effectiveness in preventing fatal arrhythmias. If the drug treatment is not effective, radiofrequency catheter ablation can be considered. However, it may be difficult to target accurately the right spot, and the attempt of the radiofrequency catheter ablation failed. Therefore, after ineffective medical treatment, implantable cardioverter-defibrillator implantation could be an option for patients with life-threatening cardiac events.